BCAL Diagnostics presents BREASTESTplus™ 2 research at international lipidomics conference
BCAL Diagnostics (ASX: BDX) has presented a scientific poster on the research underpinning BREASTESTplus™ 2 at the Australian Lipid Meeting and International Lipidomic Society Conference in Perth, held 18-21 October 2026. The research traces the development of the company’s blood-based breast cancer detection technology, from the discovery of lipid biomarkers associated with breast cancer through to assay development and validation.
The poster is titled “Clinical Translation of Targeted Lipidomics: Validation of BREASTESTplus™ 2 for Early Breast Cancer Detection”. Key highlights from the announcement include:
- The poster was presented at the joint Australian Lipid Meeting and International Lipidomic Society Conference
- The research provides a scientific foundation for the continued development of BREASTESTplus™
- BCAL is described as a global pioneer in commercialising lipid-based cancer detection technology
The poster is available on the BCAL website. For investors, the presentation offers exposure for the science behind the company’s core product, though the announcement does not disclose the poster’s results or any financial data.
When big ASX news breaks, our subscribers know first
Why the science matters for BCAL
A pioneer in lipid-based detection
BCAL’s BREASTESTplus™ test is “believed to be the first commercially available cancer detection test globally to use blood lipid biomarkers”, according to the announcement. The company says it translates advances in lipidomic research into a diagnostic tool available to patients.
BREASTESTplus™ is a simple, non-invasive blood test used in conjunction with mammography. It was launched as a “rule-out” test for the clinical evaluation of breast disease in women with dense breasts.
Building awareness and engagement
The company states that sharing the methodology with an international scientific audience supports greater awareness of its technology and its potential clinical applications. Stronger scientific credibility could, over time, support clinician and stakeholder confidence, although the announcement makes no such claim.
Anne-Louise Arnett, Chief Executive Officer
“The science underpinning our technology has been built through years of research… Sharing this work with the broader scientific community is an important step in building awareness, encouraging scientific engagement and strengthening the evidence base supporting our technology.”
Lipidomics explained: what it means for early cancer detection
Lipidomics is the study of lipids (fats) in the body. The announcement describes BCAL’s work as beginning with the discovery of lipid biomarkers associated with breast cancer, which are measurable markers found in blood.
The joint conference unites researchers, scientists, clinicians and industry leaders from around the world to share discoveries and promote collaboration in lipidomics, lipid biology and related technologies.
| Fact | Impact |
|---|---|
| Poster presented at the international conference | Exposure to a global scientific audience |
| Research covers biomarker discovery to validation | Demonstrates the scientific pathway behind the test |
| Poster publicly available | Transparent access to the methodology |
What’s next for BREASTESTplus™
The announcement provides no timelines, financial targets or commercial milestones. It states only that the research provides a scientific foundation for the continued development of BREASTESTplus™.
The BREASTESTplus 2 validation results reported 80.3% sensitivity and 48.5% specificity for early-stage detection across all breast densities, with a three-city commercial launch now planned for November 2026.
BCAL also holds an exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.
Readers can review the poster and further company information on the BCAL Diagnostics website.
Don’t Miss the Next Healthcare Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to their inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive healthcare alerts the moment market-moving announcements break, before the wider market catches up.